Cargando…

Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus

Detalles Bibliográficos
Autores principales:	Vernino, Steven, Claassen, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Case Vignette
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524866/ https://www.ncbi.nlm.nih.gov/pubmed/28674868 http://dx.doi.org/10.1007/s10286-017-0435-5

Ejemplares similares

Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Claassen, Daniel, et al.
Publicado: (2017)

Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Goodman, Brent P., et al.
Publicado: (2017)

Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease
por: Kremens, Daniel, et al.
Publicado: (2017)

Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension
por: Vernino, Steven, et al.
Publicado: (2017)

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017)

Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension
por: Mehdirad, Ali, et al.
Publicado: (2017)

Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy
por: Goodman, Brent P., et al.
Publicado: (2017)

Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease
por: Gupta, Fiona, et al.
Publicado: (2017)

2198 Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension
por: McDonell, Katherine, et al.
Publicado: (2018)

Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension
por: François, Clément, et al.
Publicado: (2019)

Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Lew, Mark, et al.
Publicado: (2017)

Neurogenic orthostatic hypotension – management update and role of droxidopa
por: Vijayan, Joy, et al.
Publicado: (2015)

Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
por: Biaggioni, Italo, et al.
Publicado: (2017)

Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa
por: Isaacson, Stuart H, et al.
Publicado: (2014)

Use of droxidopa for the long-term treatment of neurogenic orthostatic hypotension
por: Raj, Satish R, et al.
Publicado: (2019)

Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
por: François, Clément, et al.
Publicado: (2016)

Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension
por: Hauser, Robert A., et al.
Publicado: (2016)

Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
por: Kaufmann, Horacio
Publicado: (2017)

Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach
por: Amjad, Fahd, et al.
Publicado: (2021)

Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review
por: Hoxhaj, Pranvera, et al.
Publicado: (2023)

Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa
por: Biaggioni, Italo, et al.
Publicado: (2015)

Erratum to: Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017)

Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial
por: Kaufmann, Horacio, et al.
Publicado: (2014)

Characterization of the changes in supine blood pressure with long‐term use of droxidopa in patients with neurogenic orthostatic hypotension
por: Hewitt, L. Arthur, et al.
Publicado: (2021)

Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment
por: Hauser, Robert A., et al.
Publicado: (2022)

Erratum to: Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease
por: Gupta, Fiona, et al.
Publicado: (2017)

Psychometric validation of a patient-reported single-item assessment of ‘Good Day Bad Day’ in a neurogenic orthostatic hypotension population treated with droxidopa
por: François, Clément, et al.
Publicado: (2022)

Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report
por: Ho, Annie H., et al.
Publicado: (2020)

Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer
por: Cutsforth-Gregory, Jeremy K., et al.
Publicado: (2019)

Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension
por: Eisenhofer, Graeme, et al.
Publicado: (2021)

Neurogenic orthostatic hypotension: the very basics
por: Kaufmann, Horacio, et al.
Publicado: (2017)

Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient with Cardiovascular Disease and Parkinson's Disease
por: McCullough, Peter A.
Publicado: (2019)

Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers
por: Claassen, Daniel O., et al.
Publicado: (2018)

Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management
por: Metzler, Manuela, et al.
Publicado: (2012)

The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension
por: Gibbons, Christopher H., et al.
Publicado: (2017)

Neurogenic Orthostatic Hypotension: State of the Art and Therapeutic Strategies
por: Kalra, Dinesh K, et al.
Publicado: (2020)

Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
Publicado: (2020)

Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
por: Byun, Jung‐Ick, et al.
Publicado: (2019)

Neurogenic orthostatic hypotension with Parkinson's disease as a cause of syncope: A case report
por: Li, Ya, et al.
Publicado: (2021)

Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms
por: Eschlböck, Sabine, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vt7if8gk2daaco3s1u512b4u5l